GFAP as a novel HIV/neuroAIDS biomarker
GFAP 作为一种新型 HIV/神经艾滋病生物标志物
基本信息
- 批准号:8098194
- 负责人:
- 金额:$ 6.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS Dementia ComplexAIDS neuropathyAcquired Immunodeficiency SyndromeAddressAffectAgreementAstrocytesAstrocytosisBiochemicalBiochemical GeneticsBiological MarkersBlood - brain barrier anatomyBrainBrain DiseasesCCL2 geneCD4 Positive T LymphocytesCXCL10 geneCalciumCaringCategoriesCellsCentral Nervous System InfectionsCerebrospinal FluidCessation of lifeCognitiveDevelopmentDiseaseDisease ProgressionEndoplasmic ReticulumFascicleFunctional disorderGene ExpressionGenetic TranscriptionGiant CellsGlial Fibrillary Acidic ProteinGoalsHIVHIV InfectionsHIV-1Highly Active Antiretroviral TherapyHomeostasisHumanImpaired cognitionIndividualInfectionInjection of therapeutic agentIntegration Host FactorsInterleukin-1Interleukin-6JournalsKnowledgeLaboratoriesLifeLinkLymphocyteMediatingMediator of activation proteinMicrogliaMinorMolecularMolecular ProfilingMonitorMotorMusMyelinNerve DegenerationNeuraxisNeurogliaNeurologicNeurologic DysfunctionsNeuronsPallorPathogenesisPathologyPatientsPharmacologyProcessPropertyProteinsRecruitment ActivityResourcesRoleSamplingSignal TransductionSocial ImpactsStagingSymptomsTestingTherapeuticTransgenic MiceViralantiretroviral therapybiological adaptation to stressbrain cellbrain tissuecerebral atrophychemokinecohortcytokineeconomic impactendoplasmic reticulum stressfetalimmune activationmacrophagemonocytemotor disorderneurobehavioralneuron apoptosisneuronal survivalneuropathologyneurotoxicitynovelnovel markernovel therapeuticspreventprotein activationprotein aggregateprotein aggregationprotein expressionprotein functionpublic health relevancetat Proteintranscription factortreatment response
项目摘要
DESCRIPTION (provided by applicant): HIV-1 infection of the central nervous system (CNS) occurs in a majority of AIDS patients and causes a variety of neurologic dysfunction and neuropathologies generally termed neuroAIDS. Microglia/macrophages, and astrocytes to a less extent are the main target cells for HIV-1 infection in the CNS, whereas neurons are rarely infected by HIV-1 but mostly affected in HIV/neuroAIDS. Therefore, several indirect mechanisms have been proposed for HIV/neuroAIDS pathogenesis. Among them is HIV-1 Tat protein. We have shown that Tat expression in the absence of HIV-1 infection is sufficient to cause neurobehavioral abnormalities and pathologies similar to most of those noted in HIV/neuroAIDS. Moreover, we have shown that Tat activates glial fibrillary acidic protein (GFAP) expression in astrocytes and results in astrocyte dysfunction and subsequent neuron death. Furthermore, our preliminary studies have found that Tat-activated GFAP expression involves a network of transcription factors and is associated with GFAP aggregates and endoplasmic reticulum (ER) stress in astrocytes and impaired neuron survival. Importantly, we have also obtained preliminary evidence to link the cerebrospinal fluid (CSF) levels to HIV/neuroAIDS pathogenesis. As a logical extension of our studies, we propose to further dissect the GFAP function in Tat neurotoxicity and HIV/neuroAIDS pathogenesis. Besides, we will determine the feasibility of using the CSF GFAP level as a novel HIV/neuroAIDS biomarker. Thus, the underlying hypothesis for the current proposal is that Tat adversely affects astrocyte function and neuronal survival through GFAP activation/aggregation and ER stress. In other words, GFAP is not only a mediator but also an indicator of Tat neurotoxicity and HIV/neuroAIDS pathogenesis. To test this hypothesis, we propose to address the following interrelated specific aims: (1) To characterize the relationship between GFAP expression and ER stress in astrocytes; (2) To determine effects of Tat-activated GFAP expression/aggregation and ER stress on astrocytes; (3) To define the molecular mechanisms of GFAP-/ER stress-mediated neurotoxicity; and (4) To investigate the potential of using GFAP as a novel HIV/neuroAIDS biomarker. We will use a combined molecular, cellular, biochemical, and genetic approach, including use of primary mouse cortical astrocyte cultures and neuron cultures, Tat transgenic mice, GFAP-null/Tat transgenic mice, primary human fetal brain cultures, embedded brain tissues and CSF samples of a large HIV-1 cohort in our studies. The answers sought have fundamental significance for understanding of this critical and pervasive protein GFAP, and its role in HIV/neuroAIDS pathogenesis. In addition, these answers shall also aid in identification of HIV/neuroAIDS biomarkers and development of anti-HIV/neuroAIDS therapeutic strategies.
PUBLIC HEALTH RELEVANCE: HIV-1 infection often causes a number of brain diseases and affects the ability of people to care for themselves and thus the quality of their daily life. The social and economic impact cannot be overemphasized. The current study seeks to have a better understanding of the host factors that are important for the disease progression and then use the knowledge acquired to develop new markers to monitor the disease progression and treatment response and develop new therapeutics.
描述(由申请人提供):HIV-1感染中枢神经系统(CNS)发生在大多数AIDS患者中,并导致各种神经功能障碍和神经病理学,通常称为neuroAIDS。小胶质细胞/巨噬细胞和星形胶质细胞在较小程度上是CNS中HIV-1感染的主要靶细胞,而神经元很少被HIV-1感染,但在HIV/neuroAIDS中主要受影响。因此,已经提出了几种间接机制的HIV/neuroAIDS发病机制。其中包括HIV-1达特蛋白。我们已经证明,在没有HIV-1感染的情况下,达特表达足以引起神经行为异常和与HIV/neuroAIDS中所注意到的大多数类似的病理。此外,我们已经表明,达特激活胶质细胞酸性蛋白(GFAP)的表达,星形胶质细胞功能障碍和随后的神经元死亡的结果。此外,我们的初步研究发现,Tat激活的GFAP表达涉及转录因子的网络,并与星形胶质细胞中的GFAP聚集体和内质网(ER)应激以及受损的神经元存活相关。重要的是,我们还获得了将脑脊液(CSF)水平与HIV/neuroAIDS发病机制联系起来的初步证据。作为我们研究的逻辑延伸,我们建议进一步剖析GFAP在达特神经毒性和HIV/neuroAIDS发病机制中的功能。此外,我们将确定使用CSF GFAP水平作为新的HIV/neuroAIDS生物标志物的可行性。因此,当前提议的基本假设是达特通过GFAP活化/聚集和ER应激不利地影响星形胶质细胞功能和神经元存活。换句话说,GFAP不仅是一种介质,也是达特神经毒性和HIV/neuroAIDS发病机制的指标。为了验证这一假设,我们提出了以下相互关联的具体目标:(1)表征星形胶质细胞中GFAP表达与ER应激之间的关系;(2)确定Tat激活的GFAP表达/聚集和ER应激对星形胶质细胞的影响;(3)确定GFAP/ER应激介导的神经毒性的分子机制;(4)探讨GFAP作为HIV/neuroAIDS生物标志物的可能性。我们将使用分子、细胞、生物化学和遗传学相结合的方法,包括使用原代小鼠皮质星形胶质细胞培养物和神经元培养物、达特转基因小鼠、GFAP-null/达特转基因小鼠、原代人胎脑培养物、包埋脑组织和大量HIV-1队列的CSF样本进行研究。寻求的答案对于理解这种关键和普遍的蛋白GFAP及其在HIV/neuroAIDS发病机制中的作用具有根本意义。此外,这些答案还有助于识别HIV/neuroAIDS生物标志物和开发抗HIV/neuroAIDS治疗策略。
公共卫生相关性:HIV-1感染通常会导致一些脑部疾病,并影响人们照顾自己的能力,从而影响他们的日常生活质量。社会和经济影响怎么强调都不过分。目前的研究旨在更好地了解对疾病进展重要的宿主因素,然后利用所获得的知识开发新的标志物来监测疾病进展和治疗反应,并开发新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Johnny J He其他文献
Johnny J He的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Johnny J He', 18)}}的其他基金
miR-132 a new player in HIV/neuroAIDS
miR-132 是艾滋病毒/神经艾滋病的新参与者
- 批准号:
10129140 - 财政年份:2015
- 资助金额:
$ 6.91万 - 项目类别:
miR-132, a new player in HIV/neuroAIDS
miR-132,艾滋病毒/神经艾滋病的新参与者
- 批准号:
8998527 - 财政年份:2015
- 资助金额:
$ 6.91万 - 项目类别:
GFAP as a novel HIV/neuroAIDS biomarker
GFAP 作为一种新型 HIV/神经艾滋病生物标志物
- 批准号:
8245166 - 财政年份:2010
- 资助金额:
$ 6.91万 - 项目类别:
GFAP as a novel HIV/neuroAIDS biomarker
GFAP 作为一种新型 HIV/神经艾滋病生物标志物
- 批准号:
8442887 - 财政年份:2010
- 资助金额:
$ 6.91万 - 项目类别:
HIV interaction with drugs of abuse and adult neurogenesis
HIV与滥用药物和成人神经发生的相互作用
- 批准号:
8411332 - 财政年份:2010
- 资助金额:
$ 6.91万 - 项目类别:
GFAP as a novel HIV/neuroAIDS biomarker
GFAP 作为一种新型 HIV/神经艾滋病生物标志物
- 批准号:
8644917 - 财政年份:2010
- 资助金额:
$ 6.91万 - 项目类别: